[Skip to Content]
[Skip to Content Landing]
Views 196
Citations 0
Correction
July 2018

Incorrect Numbers of Adverse Events Reported

JAMA Intern Med. 2018;178(7):1003. doi:10.1001/jamainternmed.2018.2967

The Original Investigation titled “Azithromycin for Acute Exacerbations of Asthma: The AZALEA Randomized Clinical Trial,”1 published in the November 2016 issue of JAMA Internal Medicine, reported incorrect numbers of adverse events owing to a recently discovered error in the AZALEA clinical trial database. In the last paragraph of the Results section, “a reduced frequency of respiratory, thoracic, and mediastinal (63 of 64 respiratory) adverse events (27 vs 37, respectively)” should read “a reduced frequency of respiratory, thoracic, and mediastinal (61 of 62 respiratory) adverse events (26 vs 36, respectively).” In the online-only Supplement, numbers of adverse events were reported incorrectly in eTables 16 through 19. This article and its supplement have been corrected online.

References
1.
Johnston  SL, Szigeti  M, Cross  M,  et al; AZALEA Trial Team.  Azithromycin for acute exacerbations of asthma: the AZALEA randomized clinical trial.  JAMA Intern Med. 2016;176(11):1630-1637. doi:10.1001/jamainternmed.2016.5664PubMedGoogle ScholarCrossref
×